TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32372294
Drug: ER ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER ambroxol 75-mg retard capsules once daily
Study: 32372294
Drug: IR ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR ambroxol 60-mg effervescent tablets twice daily
Study: 32372294
Drug: IR ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR ambroxol 30-mg tablets twice daily
Study: 32372416
Drug: DLL3-targeting antibody-drug
Normalized name: antibody-drug conjugate DP303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLL3-targeting antibody-drug conjugate (Rovalpituzumab tesirine - Rova-T)
Study: 32372672
Drug: PD-1 inhibitor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor, sintilimab, administered for three cycles.
Study: 32373171
Drug: Spa treatment
Normalized name: Salicylic Acid 5 mg in 1 mL TOPICAL LOTION [ageLOC LumiSpa Treatment Cleanser Acne]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa treatment with radon water
Study: 32374868
Drug: Clinical and
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and imaging follow-up without occlusion treatment
Study: 32375814
Drug: Transcatheter rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter rectal arterial chemoembolization (TRACE) with oxaliplatin and S-1 concurrent chemoradiotherapy (NATRACE-CRT)
Study: 32375814
Drug: Standard fluorouracil-based
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard fluorouracil-based combined modality treatment (NA-CRT)
Study: 32375872
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) treatment
Study: 32377266
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Therapy
Study: 32377287
Drug: Outpatient clinic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient clinic therapy
Study: 32377978
Drug: DFP-11207, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFP-11207, administered orally daily, doses escalating from 40 mg/m²
Study: 32379640
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (8 weekly sessions)
Study: 32380537
Drug: Varlilumab (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varlilumab (0.1, 0.3, 1, 3, or 10 mg/kg IV) as a single dose with a 28-day observation period, followed by weekly dosing (4 doses per cycle, up to 5 cycles)
Study: 32380537
Drug: Varlilumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varlilumab (0.3 mg/kg every 3 weeks, 4 doses per cycle, up to 5 cycles) in an expansion cohort of 4 patients with Hodgkin lymphoma
Study: 32380536
Drug: Dose-dense immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense immunochemotherapy with early systemic CNS prophylaxis (2 courses of high-dose methotrexate, biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOEP and 1 course of high-dose cytarabine with R, plus intrathecal liposomal cytarabine at courses 1, 3, and 5)
Study: 32380538
Drug: Ivosidenib (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (targeted mutant IDH1 enzyme inhibitor)
Study: 32381080
Drug: Anti-mycobacterial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-mycobacterial treatment
Study: 32381098
Drug: Qinbudan tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen (isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin for 2 months, followed by isoniazid, rifampicin, ethambutol for 6 months)
Study: 32381098
Drug: Qinbudan tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinbudan tablet (QBDT) as adjunct therapy with standard anti-TB regimen
Study: 32381495
Drug: Clinic-based directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based directly observed therapy (DOT)
Study: 32381630
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg orally per day for 12 months
Study: 32382714
Drug: H4:IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H4:IC31 vaccine (2 doses IM 56 days apart)
Study: 32382714
Drug: H56:IC31 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H56:IC31 vaccine (2 doses IM 56 days apart)
Study: 32382714
Drug: BCG revaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG revaccination (single dose ID)
Study: 32383099
Drug: Alternative approaches
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative approaches (e.g., prevalence function, Q-TWiST, ToxT, recurrent event approaches)
Study: 32383192
Drug: Bendamustine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine plus rituximab (first-line treatment)
Study: 32383192
Drug: Bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), fludarabine, or ibrutinib (second-line treatment)
Study: 32383296
Drug: Temporally Feathered
Normalized name: Gallus gallus feather
DrugBank: Gallus gallus feather (DB10420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporally Feathered Radiation Therapy (TFRT)
Study: 36574408
Drug: Internet Attachment-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Attachment-Based Compassion Therapy (iABCT)
Study: 32384884
Drug: Vortioxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine treatment for 8 weeks
Study: 32385144
Drug: Immunotherapic vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapic vaccine comprising phosphorylated BCAR3 peptide
Study: 32385144
Drug: Immunotherapic vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapic vaccine comprising phosphorylated IRS2 peptide
Study: 32385603
Drug: Isoglycaemic intravenous
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoglycaemic intravenous glucose infusions (IGIVI)
Study: 32385845
Drug: 0.2% sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% sirolimus gel applied twice daily for > 52 weeks (maximum 136 weeks)
Study: 32386106
Drug: Video directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video directly observed therapy (VDOT) adherence
Study: 32386568
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg) plus carboplatin and nab-paclitaxel (100 mg/m²) as neoadjuvant treatment.
Study: 32387010
Drug: HIVAX therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVAX therapeutic HIV vaccine
Study: 32388060
Drug: Registry data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registry data collection from 232 MG patients
Study: 32389183
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg) and glecaprevir-pibrentasvir (300 mg/120 mg) given one dose 6-12 hours before transplant and once a day for 7 days after surgery (total of 8 doses)
Study: 32389229
Drug: Qualitative interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative interviews and smartphone/tablet app reporting
Study: 32390277
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg once daily for 7 days in a 28-day cycle)
Study: 32392512
Drug: Oral glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoids (prednisolone-equivalent dose)
Study: 32392512
Drug: Cumulative glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative glucocorticoid prednisolone-equivalent dose
Study: 32393358
Drug: Validated paradigms
Approvals — FDA: no, EMA: no, PMDA: no
Description: Validated paradigms (e.g., fear conditioning, reward anticipation, imaging stress test, social reward learning task)
Study: 32394292
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OACs) including dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban
Study: 32395337
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 or 100 mg
Study: 32395709
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system at a maximum dose of 160 mg/day
Study: 32395709
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) administered via implanted intra-cerebroventricular delivery system
Study: 32396014
Drug: One prior
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One prior administration of nivolumab and the cohort A regimen (5-FU+CDDP)
Study: 32396014
Drug: One prior
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One prior administration of nivolumab and the cohort C regimen (docetaxel+ CF)
Study: 32396615
Drug: CWP232291 (CWP291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CWP232291 (CWP291) administered IV daily for 7 days every 21 days
Study: 32398128
Drug: Electrodermal activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrodermal activity (EDA) assessment during exposure therapy
Study: 32398128
Drug: Subjective Units
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective Units of Distress Scale (SUDS) during exposure therapy
Study: 32398478
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg subcutaneously
Study: 32398792
Drug: elotuzumab therapy
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: elotuzumab therapy
Study: 32399045
Drug: Bone Marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone Marrow Concentrate (BMC) with Platelet-Rich Plasma (PRP) and Platelet Lysate (PL) injections
Study: 32399214
Drug: shRNA-IL6-modified anti-CD19
Normalized name: Anti-CD19 humanized monoclonal antibody conjugated to DM4
DrugBank: Coltuximab ravtansine (DB06342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: shRNA-IL6-modified anti-CD19 CAR-T therapy (ssCAR-T-19)
Study: 32399263
Drug: MVT-5873 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVT-5873 (a cytotoxic monoclonal antibody targeting CA 19-9) administered as a single dose three days before resection and four post-operative infusions.
Study: 32905959
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity
Study: 32401302
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk insulin and leptin
Study: 32401707
Drug: 0.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL/kg 0.25% bupivacaine (Group B)
Study: 32401707
Drug: 0.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL/kg 0.25% bupivacaine + 3 mg/kg 1% lidocaine (Group BL)
Study: 32401707
Drug: Intra-operative intravenous
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-operative intravenous fentanyl use
Study: 32401731
Drug: Braden Pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braden Pressure Ulcer Risk Assessment conducted weekly.
Study: 32401744
Drug: Revefenacin (LAMA)
DrugBank: Revefenacin (DB11855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Revefenacin (LAMA) and Formoterol Fumarate (LABA) inhalation solution admixture
Study: 32403379
Drug: Liposomal anthralin
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal anthralin gel
Study: 32403379
Drug: Ethosomal anthralin
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethosomal anthralin gel
Study: 32404003
Drug: Transference work
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transference work in psychodynamic therapy
Study: 32404091
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of pancreatic metastases
Study: 32404437
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin at 75-100 mg/kg/day divided doses
Study: 32404868
Drug: Radium-223 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 with bone health agents (BHAs)
Study: 32405431
Drug: Phosphorus supplementation
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus supplementation (400 mg) with glucose
Study: 32405623
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg albendazole (PSAC)
Study: 32405623
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg albendazole (SAC)
Study: 32405623
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole (Adults)
Study: 32407157
Drug: Invasive Tracheobronchial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive Tracheobronchial Aspergillosis treatment; specific intervention details not available
Study: 32407400
Drug: Maternal genetic
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal genetic locus ITPR1 (rs746039 [G])
Study: 32407591
Drug: Guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 200 mg (subcutaneous)
Study: 32407591
Drug: Probe cocktail
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probe cocktail (midazolam, S-warfarin, omeprazole, dextromethorphan, caffeine)
Study: 32408984
Drug: Chimeric Antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric Antigen Receptor T-Cells (CAR-T)
Study: 32410049
Drug: Transdiagnostic adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic adherence counseling and cognitive behavioral therapy
Study: 32410080
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg twice daily plus cetuximab (weekly intravenous at approved dose)
Study: 32410080
Drug: Capmatinib (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capmatinib (150, 300, and 400 mg) plus cetuximab
Study: 32410617
Drug: Model-based personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-based personalized robot-aided rehabilitation therapy
Study: 32410670
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT) implementation
Study: 32411374
Drug: 16-week supervised
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16-week supervised heavy resistance training program with weekly undulating periodization
Study: 32411381
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation group therapy (BA) in addition to usual care
Study: 32411717
Drug: Intravenous Cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Cyclophosphamide, dosage and duration not available
Study: 32412142
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficient group (serum 25OHD ≥ 20 ng/mL)
Study: 32412142
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficient group (serum 25OHD 10-20 ng/mL)
Study: 32412142
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficient group (serum 25OHD ≤ 10 ng/mL)
Study: 32412142
Drug: Serum 25OHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25OHD < 20 ng/mL
Study: 32412142
Drug: Serum 25OHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25OHD ≥ 20 ng/mL
Study: 32414330
Drug: Bioresorbable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresorbable polymer drug-eluting stent (BP-DES)
Study: 32414346
Drug: Ready-to-use food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands for a maximum of 9-12 months.
Study: 32414346
Drug: Ready-to-use food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-use food (RUF) provided according to WHO prescription weight- and age-bands.
Study: 32414827
Drug: Centralised Chronic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Centralised Chronic Medication Dispensing and Distribution (CCMDD) programme
Study: 32414848
Drug: Entospletinib +
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entospletinib + Vincristine chemotherapy
Study: 32414850
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP)
Study: 32415705
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) - high-dose
Study: 32415705
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) - low-dose
Study: 32415708
Drug: HSK3486 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 (0.4 mg/kg)
Study: 32416764
Drug: Panitumumab-IRDye800CW 25
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab-IRDye800CW 25 mg
Study: 32416764
Drug: Panitumumab-IRDye800CW 50
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab-IRDye800CW 50 mg
Study: 32416764
Drug: Panitumumab-IRDye800CW 75
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab-IRDye800CW 75 mg
Study: 32416764
Drug: Panitumumab-IRDye800CW (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab-IRDye800CW (all doses)
Study: 32418789
Drug: PCV13 vaccination
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 vaccination (3 doses with a minimum of 1 month interval between treatment courses)
Study: 32419586
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antiplatelet therapy (APT) during noncardiac surgery
Study: 32419586
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antiplatelet therapy (APT) during noncardiac surgery
Study: 32419679
Drug: Valbenazine 40
Normalized name: valbenazine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine 40 mg/day, escalated to 80 mg/day after week 4 based on tolerability and clinical assessment of TD.
Study: 32419949
Drug: Combined bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bowel preparation (2L polyethylene glycol solution night before CE, 5mL simethicone and 5mg metoclopramide 20 minutes prior to CE, right lateral position 30 minutes after swallowing CE)
Study: 32420402
Drug: Artemisinin-based combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-based combination therapies
Study: 32423477
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with epirubicin/docetaxel for 6 cycles, supplemented with bevacizumab in cycles 3-6
Study: 32423837
Drug: Pembrolizumab 200mg
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg intravenously every 3 weeks until confirmed progression, intolerable toxicity, patient withdrawal, or 24 months of therapy.
Study: 32424028
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antimalarial treatment)
Study: 32425736
Drug: GBCK25 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBCK25 (500 mg/day)
Study: 32425736
Drug: GBCK25 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBCK25 (125 mg/day)
Study: 32425926
Drug: T cell-based
Normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell-based immunotherapy targeting alpha-fetoprotein (AFP)
Study: 32427279
Drug: Early corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early corticosteroid (methylprednisolone 0.5 to 1 mg/kg/day for 3 days)
Study: 32427581
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies against CIDRα1.7 and CIDRα1.8
Study: 32427581
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies against CIDRγ3
Study: 32428369
Drug: Susceptibility-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Susceptibility-guided therapy (14-day triple or quadruple therapy based on susceptibility to clarithromycin, levofloxacin, and metronidazole)
Study: 32428369
Drug: All regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: All regimens of susceptibility-guided therapy